Managing Partner (based in Montreal)
Dr. Hubert Birner
Managing Partner (based in Montreal) Dr. Birner is responsible for TVM Capital Life Sciences’ overall investment strategy going forward and the fund operations in North America and Europe. Dr. Birner joined TVM Capital in 2000 as an investment manager. He is responsible for numerous active investments in Europe as well as the United States. He currently serves as Chairman of the Board of Argos Therapeutics Inc. (Durham, North Carolina) and is a member of the Board of Directors of Proteon Therapeutics, Inc (Kansas City, Missouri) and SpePharm Holding BV (Amsterdam, NL). Over many years, he was the Chairman/Vice Chairman of Direvo Biotech AG (Cologne, Germany) and Jerini AG (Berlin, Germany) which were acquired in 2008 by Bayer HealthCare AG and Shire Ltd. respectively.
Before joining TVM Capital, he was Head of Business Development Europe and Director of Marketing for Germany at Zeneca. Hubert joined Zeneca from McKinsey & Company’s European Health Care and Pharmaceutical practice. As a management consultant, he gained extensive experience in R&D management; marketing and sales; and joint venture structuring and business development. Dr. Birner was also an Assistant Professor for biochemistry at the Ludwig-Maximilian-University in Munich. In this capacity, he directed various research projects for large pharmaceutical companies. Dr. Birner holds an MBA from Harvard Business School and a doctoral degree in biochemistry from Ludwig-Maximilian-University Munich, where he graduated summa cum laude. His doctoral thesis was honored with the Hoffmann-La Roche prize for outstanding basic research in metabolic diseases.